Abstract
Background: Indoleamine 2,3-dioxygenase (IDO), an immunomodulatory enzyme, facilitates immune escape of tumours and promotes tumour progression. Systemic therapy with the combination of IDO and PD-1 inhibitors have resulted in significantly improved clinical efficacy and response rates in patients with advanced stage metastatic melanoma. However, there is currently only very limited data on IDO expression in melanoma, and a deeper understanding of the changes that occur during the different stages of disease progression are critical for evaluating IDO expression as a predictive biomarker for directing precision immunotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
